
The dengue vaccine Qdenga, pre-approved by the WHO, has demonstrated over 50% efficacy in reducing cases, with lasting protective effects and a strong safety profile. A global review of 19 studies involving 20,000 participants found that over 90% of recipients developed immunity against all four dengue virus serotypes. The vaccine, developed by Takeda Pharmaceutical, holds promise as a key tool in dengue prevention, especially in endemic regions.
Like
Save
Share